Receptor expression sheds light on nasal polyposis

NewsGuard 100/100 Score

The increased expression of a leukotriene receptor and a glucocorticoid receptor (GR) may contribute to the development of nasal polyposis, report researchers.

Furthermore, the addition of a cysteinyl leukotriene 1 (CysLT1) receptor agonist may confer an additional benefit on nasal polyposis that is resistant to steroid treatment alone.

Recent studies have demonstrated an important role for GRs in steroid resistance in nasal polyps, explain Chae-Seo Rhee (Seoul National University College of Medicine, Korea) and colleagues. In addition, it has been suggested that cysteinyl leukotrienes (CysLTs) are involved in the development of nasal polyps, the biological action of which is partly mediated by the CysLT1 receptor.

As reported in the European Archives of Otorhinolaryngology, the team analyzed nasal biopsies from 32 individuals with chronic rhinosinusitis and nasal polyposis who were resistant to corticosteroid therapy and compared them with samples of middle turbinate tissue from seven healthy controls.

The researchers found that the number of CysLT1 receptor-positive cells was significantly higher in those with nasal polyps than among those with normal tissue, at 281 cells/mm2 versus 157 cells/mm2. The percentage of cells expressing CysLT1 receptor was also significantly increased in the nasal polyps versus normal turbinate groups, at 21.3% versus 10.6%.

There was no significant difference in GR-α expression between the two sample groups, but GR-β expressing cells were significantly more abundant in nasal polyps than in normal tissues, at 36 cells/mm2 vs 19 cells/mm2. And GR-β positive cells were significantly increased in nasal polyp compared with control samples, at 2.5% versus 1.1%.

Interestingly, while no relationship was found between CysLT-1 receptor and GR-α expression in the nasal polyp samples, CysLT-1 receptor significantly correlated with GR-β expression in nasal polyps in both cell count and the proportion.

"The predominance of CysLT1 receptor in GR-β over-expressed polyps provides a hint for a positive effect of LTRA [leukotriene receptor agonists] as an adjuvant therapy on steroid-unresponsive nasal polyps," say the researchers. "The combination of LTRA and corticosteroids could produce clinical efficacy for treatment of nasal polyposis."

However, "more controlled studies of LTRA add-on therapy in nasal polyps are necessary for reliable data," they conclude.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Receptor expression sheds light on nasal polyposis. News-Medical. Retrieved on April 13, 2024 from

  • MLA

    Robertson, Sally. "Receptor expression sheds light on nasal polyposis". News-Medical. 13 April 2024. <>.

  • Chicago

    Robertson, Sally. "Receptor expression sheds light on nasal polyposis". News-Medical. (accessed April 13, 2024).

  • Harvard

    Robertson, Sally. 2018. Receptor expression sheds light on nasal polyposis. News-Medical, viewed 13 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New hope for binge eating and bulimia: GLP-1 drugs could be the key